Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

chinadaily.com.cn - Pharma firms obliged to make medicines even if unprofitable - Opinion
Pharma firms obliged to make medicines even if unprofitable - Opinion
中国日报网

Man buys medicine with the help of a pharmacy sales person in Chongqing municipality, Southwest China, July 21, 2014. [Photo/IC] AFTER MEDIA REPORTS about a shortage, even in some big hospitals, of mercapatopurinem, a medication used to treat…

fool.com - Motley Fool Transcribing - Rhythm Pharma (RYTM) Earnings Call Transcript
Rhythm Pharma (RYTM) Earnings Call Transcript
The Motley Fool

Thursday, Feb. 26, 2026 at 8 a.m. ET Chairman, Chief Executive Officer, and President — David P. Meeker Executive Vice President, Head of North America — Jennifer Lee Chief Financial Officer — Hunter C. Smith Executive Vice…

thehindubusinessline.com - Eugia Pharma gets USFDA nod for Everolimus tablets
Eugia Pharma gets USFDA nod for Everolimus tablets
BusinessLine

Eugia Pharma Specialities, an arm of Aurobindo Pharma, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus tablets. The approved drug is a bioequivalent and therapeutically equivalent to…

marketbeat.com - Oppenheimer Issues Pessimistic Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price
Oppenheimer Issues Pessimistic Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price
MarketBeat

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its target price decreased by equities researchers at Oppenheimer from $83.00 to $81.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an…

marketbeat.com - BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $95.00 at Truist Financial
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $95.00 at Truist Financial
MarketBeat

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its price objective upped by equities research analysts at Truist Financial from $86.00 to $95.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The…

marketbeat.com - Ascendis Pharma A/S $ASND Stake Decreased by Westfield Capital Management Co. LP
Ascendis Pharma A/S $ASND Stake Decreased by Westfield Capital Management Co. LP
MarketBeat

Westfield Capital Management Co. LP lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,259,909 shares of the…

rediff.com - Sohini Das - AI is fast becoming central to how drugs will be discovered
AI is fast becoming central to how drugs will be discovered
Rediff.com

India may not become a true innovation hub in five years, but could get there over the next decade or more. 'Pharma must move quickly from scale to substance'. 'The industry had proved its strength in manufacturing' 'Without AI, continuity of…

thehindubusinessline.com - Nifty Prediction Today - February 26, 2026: Nifty futures: Intraday trend unclear, stay out
Nifty Prediction Today - February 26, 2026: Nifty futures: Intraday trend unclear, stay out
BusinessLine

Nifty 50 began today's session with a gap-up at 25,556 compared to yesterday's close of 25,483. It is now trading at 25,550, up 0.25 per cent. The advance/decline ratio stands at 30/20, showing a bullish bias. Tech Mahindra (up 1.9 per cent) is the…

rediff.com - Nandita Malik - Stock Market Today: Sensex, Nifty50 End Mixed In Volatile Trade
Stock Market Today: Sensex, Nifty50 End Mixed In Volatile Trade
Rediff.com

Indian stock markets experienced a day of seesaw trading as Sensex and Nifty ended nearly flat, influenced by global market cues, US-Iran talks, and strategic profit-booking. Sensex and Nifty ended almost flat after a volatile trading session…

globenewswire.com - AiCuris Anti-infective Cures AG - Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
GlobeNewswire

Wuppertal, Germany, February 26, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that it has entered into a definitive agreement under which Asahi Kasei, through its wholly owned U.S. subsidiary Veloxis…

rediff.com - rediffGURU PANKAJ VYAVAHARE - I Was Laid Off Due To AI
I Was Laid Off Due To AI
Rediff.com

rediffGURU Pankaj Vyavahare, career counsellor and life coach, explains how you can survive in the age of AI. Are you someone who feels threatened by AI at work? Would you like to upskill so that you stay relevant? How can you future-proof your…

yahoo.com - Laiba Immad - Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments
Yahoo!

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is among the 20 Best Investments in 2026. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best investment stocks on our list. TheFly reported on February 20 that Truist Securities…

newswire.ca - genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
CNW

LYON, France, Feb. 26, 2026 /CNW/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's…

seekingalpha.com - SA Transcript Insights Editor - Agilent outlines $7.3B-$7.5B FY26 revenue target while expanding Ignite Operating System for margin growth (NYSE:A)
Agilent outlines $7.3B-$7.5B FY26 revenue target while expanding Ignite Operating System for margin growth (NYSE:A)
Seeking Alpha

Earnings Call Insights: Agilent Technologies (A) Q1 2026 CEO Padraig McDonnell reported '$1.8 billion in revenue, growing 4.4% on a core basis within our November guidance range.' McDonnell explained, 'End market conditions were largely consistent…

newsweek.com - Joe Grogan - Trump Admin Takes Pro-Patient Approach to Drug Prices | Opinion
Trump Admin Takes Pro-Patient Approach to Drug Prices | Opinion
Newsweek

For years, the drug-pricing debate in Washington has revolved around a familiar question: how much should the government intervene to lower costs? Democrats favored direct negotiation, while many Republicans warmed to international reference…

Receive a Daily briefing on Pharma Industry News

Get Started